06:51:22 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-05-16 X-dag ordinarie utdelning LIDDS 0.00 SEK
2024-05-15 Årsstämma
2024-02-27 Extra Bolagsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-28 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-30 X-dag ordinarie utdelning LIDDS 0.00 SEK
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-29 Årsstämma
2023-03-13 Bokslutskommuniké 2022
2023-01-09 Extra Bolagsstämma 2022
2022-11-28 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-02 X-dag ordinarie utdelning LIDDS 0.00 SEK
2022-06-01 Årsstämma
2022-05-24 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-22 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-18 Kvartalsrapport 2021-Q1
2021-05-18 X-dag ordinarie utdelning LIDDS 0.00 SEK
2021-05-17 Årsstämma
2021-02-25 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-15 X-dag ordinarie utdelning LIDDS 0.00 SEK
2020-05-14 Kvartalsrapport 2020-Q1
2020-05-14 Årsstämma
2020-02-27 Bokslutskommuniké 2019
2019-11-28 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-17 X-dag ordinarie utdelning LIDDS 0.00 SEK
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-16 Årsstämma
2019-02-28 Bokslutskommuniké 2018
2018-11-29 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-17 X-dag ordinarie utdelning LIDDS 0.00 SEK
2018-05-16 Kvartalsrapport 2018-Q1
2018-05-16 Årsstämma
2018-02-22 Bokslutskommuniké 2017
2017-11-09 Kvartalsrapport 2017-Q3
2017-10-06 Extra Bolagsstämma 2017
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-12 X-dag ordinarie utdelning LIDDS 0.00 SEK
2017-05-11 Årsstämma
2017-05-11 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-06-09 Extra Bolagsstämma 2016
2016-04-22 Årsstämma
2016-04-22 Kvartalsrapport 2016-Q1
2016-04-21 X-dag ordinarie utdelning LIDDS 0.00 SEK
2016-02-10 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-04-22 X-dag ordinarie utdelning LIDDS 0.00 SEK
2015-04-21 Årsstämma
2015-04-21 Kvartalsrapport 2015-Q1
2015-02-20 Bokslutskommuniké 2014
2014-11-11 Kvartalsrapport 2014-Q3
2014-08-21 Kvartalsrapport 2014-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
LIDDS är ett läkemedelsbolag. Bolaget utvecklar läkemedelsprodukter baserade på en patentskyddad och kliniskt testad drug delivery-teknologi. Egenskaperna hos produkterna utgör grunden för LIDDS teknologiplattform för utveckling av injicerbara läkemedelsprodukter. LIDDS är förkortningen för Local Intelligent Drug Delivery System och bolaget har sitt huvudkontor i Uppsala.
2024-08-28 10:00:00

April – June 2024

  • Net sales amounted to 0 MSEK
  • The operating result for the period was -2.4 MSEK
  • The net result was -2.4 MSEK corresponding to earnings per share of SEK -0.02
  • Cash flow from operating activities amounted to -2.9 MSEK
  • Cash and cash equivalents amounted to 8.1 MSEK

January – June 2024

  • Net sales amounted to 0 MSEK
  • The operating result for the period was -2.4 MSEK
  • The net result was -2.4 MSEK corresponding to earnings per share of SEK -0.02
  • Cash flow from operating activities amounted to -3.0 MSEK

Significant events January – June 2024

  • On the Extraordinary General Meeting of shareholders on the 9 January 2024 Daniel Lifveredson, Torbjörn Browall and Lars-Inge Sjöqvist were elected new members of the Board.
  • In January it was announced that an agreement to acquire Noviga Research AB had been signed.
  • In May, Mats Wiking was appointed new CEO from 1 September 2024.

CEO Statement

After some major changes in the company early in 2024, the second quarter has been quieter, with a focus on consolidation and cost control.

During the second quarter, work to reduce the company's operating costs continued. We have reviewed our consulting agreements and administrative costs and made the changes we can. When changing consultants, some increased costs may occur in the short term and this means that the effect has not fully taken effect yet, even if all significant differences are visible. It can also be difficult to get a clear picture of the costs by looking at the group figures. This due to the acquisition of Noviga being classified as a reverse takeover with negative goodwill as a result. To better understand the situation, it is easier to look at the legal parent company LIDDS and to add some minor costs for Noviga, to get a fair picture of the new group’s costs.

Although some of our projects have been on hold for over a year, work has been carried out in the projects. Among other things, the evaluations of service providers for the regulatory toxicological and safety pharmacology studies, that need to be carried out before the drug candidate NOV202 is ready for clinical studies, have been completed. To carry out the study, funding is required, and the Board is currently evaluating funding directly to the subsidiary Noviga. We have also continued our discussions regarding the clinical study DTX-002 with Nanodotax. The study, a clinical phase Ib study on prostate cancer patients, is planned to be carried out, but the study design is being discussed in order to minimize costs for the company. LIDDS hopes to return with information about Nanodotax in the near future.

With that, it is time for me to say thank you. My time in LIDDS has been interesting and educational. I welcome my successor Mats and wish him well.

Jenni Björnulfson, CEO and CFO

The interim report is available on the company’s website https://liddspharma.com/en/investors/financial-reports/